← Back to Search

Treatment for Hematologic and Lymphocytic Disorder

N/A
Recruiting
Led By Geoffrey DE Cuvelier, MD
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at the end of the study by year 2025
Awards & highlights

Summary

This study will validate a previously developed pediatric prognostic biomarker algorithm aimed at improving prediction of risk for the later development of chronic graft-versus-host disease (cGvHD) in children and young adults undergoing allogeneic hematopoietic stem cell transplant. By developing an early risk stratification of patients into low-, intermediate-, and high-risk for future cGvHD development (based upon their biomarker profile, before the onset of cGvHD), pre-emptive therapies aimed at preventing the onset of cGvHD can be developed based upon an individual's biological risk profile. This study will also continue research into diagnostic biomarkers of cGvHD, and begin work into biomarker models that predict clinical response to cGvHD therapies.

Eligible Conditions
  • Hematologic and Lymphocytic Disorder
  • Graft-versus-Host Disease
  • Bone Marrow Transplant
  • Blood Cancers
  • Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at the end of the study by year 2025
This trial's timeline: 3 weeks for screening, Varies for treatment, and at the end of the study by year 2025 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Baseline transplant clinical data collection at Day 0
Clinical data collection at 12 months
Clinical data collection at 24 months
+7 more
Secondary outcome measures
Demonstration of identifiable and reproducible differences in diagnostics of cGvHD and L-aGvHD
Determination of patient's risk profile and prediction of treatment responses
Other outcome measures
12 Month HAPLO blood sample collection
6 Month HAPLO blood sample collection

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor
1,451 Previous Clinical Trials
2,482,840 Total Patients Enrolled
Geoffrey DE Cuvelier, MDPrincipal InvestigatorUniversity of Manitoba / CancerCare Manitoba
Kirk R Schultz, MDPrincipal InvestigatorUniversity of British Columbia / BC Children's Hospital Research Institute
1 Previous Clinical Trials
302 Total Patients Enrolled
~72 spots leftby Sep 2025